ASCO 2025

De-escalating therapy - a step forward

TRADE: Abemaciclib in eBC

HRD and BRCA status as a new innovative staging system?

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

Intraoperative dose escalation helps to reach targeted…

Triple therapy 1st line | double therapy 2nd line - new…

Next-gen endocrine therapies and ADCs: Updates from…

AI and ADCs: Precision diagnostics & safer rechallenge…

New compounds - new approaches: TNBC | HR+ | HER2+

SG + Pembro in aTNBC: a new standard of care?

A new standard for the firstline treatment of HER2+…

A new standard for endocrine-resistant HR+ MBC?

Future new SOC for PD-L1-positive mTNBC

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

New firstline SOC for HER2+ metastatic BC

A new first-line therapy for TNBC

Final OS-Analysis of INAVO-120 trial

New AKT/PIK3 Antagonist for treatment of mBC after…

SG + Pembrolizumab might become SOC for PD-L1-positive…

Liquid biopsy as a navigator for personalized therapy…

New SOC in first-line treatment for primary endocrine…

ASCENT-04

T-DXd: Detecting ILD and treat again

Effective ADC for HER2+ mBC with brain metastases

Vepdegestrant for treatment of ER+/HER2- aBC

Re-exposition and ILD

Additional chemo-free option for TNBC

New treatment option in first line of metastatic TNBC

Sac-TMT for metastatic TNBC

Additional ADC effective for untreated TNBC

Nuovo antagonista di AKT/PIK3 per il trattamento della…

Analisi finale della OS dello studio INAVO-120

Nuova opzione di trattamento in prima linea per il TNBC…

Un nouveau traitement de première ligne pour le TNBC

Una nuova terapia di prima linea per il TNBC

Ipatasertib + Fulvestrant mejora la supervivencia libre…

SG + Pembrolizumab podría convertirse en el tratamiento…

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

PARP-inhibitor combinations in advanced prostate cancer

MMAI Model identifies patients who benfit from ARPI in…

New way of treatment for PCa

Personalized In Situ Immunotherapy SYNC-T Shows High…

Stereotactic beam radiation therapy 2.0

Localized CSPC - innovations

mHSPC - ADT + NHT updates

Immuntherapy - an evolution?

mHSPC - prognostification - indications on integration?

Real world data from ironman registry confirms…

Rebirth of Rucaparib

Adding EZH2 to Enzalutamide to decrease the development…

CAN-2409 Offers First New Option in 20 Years

Niraparib + Abiraterone Improves Outcomes in…

Combination of LU-PSMA and immunotherapy, EVOLUTION…

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

Complete but Not Finished: EV+P cCR Data Extend the SOC…

ctDNA Clearance Confirms Added Value of Perioperative…

Sasanlimab + BCG: Practice-Changing Potential for…

Benefit of IO/IO therapy in mUC

A new prognostic factor in bladder cancer?: The case of…

New option for high-risk NMIBC

The role of sansalimab (+ SG) in BCG-naive and…

NIAGARA study and circulating tumor DNA

CREST Study: Promising Results with PD-1 Inhibitor…

ASCO 2025 - Highlights for Bladder Cancer

Update on EV-PEM in the EV-302 study

mUC EVP + subsequent therapies

UTUC - enlighted

mUC - new approaches?

New nectin-4 ADCs are coming

Intensive caution of BCG Therapy

De nouveaux ADC pour la nectine-4 arrivent

El rol de sansalimab (+ SG) en el carcinoma urotelial…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

La respuesta es importante en pacientes con cáncer…

HIF alfa sigue siendo una diana interesante en el RCC y…

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

Casdatifan + Cabo – Too Early to Call It a Game…

Long-term outcome of Nnivo-Ipi in clear cell RCC

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

Nivo + Ipi - Update & Insights

First lession

HIF alpha still an interesting target in RCC and other…

5-Year OS data from the KEYNOTE-564 study

Neoadjuvant Approaches in resectable NSCLC: Insights…

Chemoimmunotherapy followed by chemoradiotherapy

Neadjuvant targeted therapy

Neoadjuvant Alectinib in resectable stage III NSCLC

CM-816: The OS results are positive and demonstrate…

Updates in perioperative strategies in NSCLC

CheckMate 816: Update on OS-benefit

cTDNA in periop chemo-IO strategies

ctDNA stratification

CM-816 : Les résultats de l'OS sont positifs et…

CheckMate 816 : Mise à jour sur les avantages du…

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

Benefit of IO is depending on the time of day of…

TROP2 targets – where is first-line development…

Updates on ADCs in EGFR resistance

Immunotherapy – before or after 3 p.m.?

Have we MET our target?

Sevarbertinib – an additional option for HER2 exon 20…

KRAS G12C: Can immunotherapy improve patient outcome…

RELA-104-biomarker-analysis

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

HER3-DXd: dissapointing negative trial

Does the timing of IO-infusion impact survival?

ADC in the 3L beats docetaxel

HERTHENA-Lung02 unfortunately negative study -…

ADC as 3L in EGFR

Is there still a place for HER3-DXd in advanced NSCLC?

HERTHENA-Lung02 étude malheureusement négative -…

KRAS G12C: Kan immunotherapie alleen het resultaat voor…

Actualizaciones sobre los ADC en la resistencia al EGFR

Hebben we ons doel gehaald?

Taralatamb - the new SOC in 2L treatment

Tarlatamab - a new SOC in second line

The first positive maintenance therapy in SCLC

New therapies to improve patient survival

New maintenance therapy for SCLC

De nouvelles thérapies pour améliorer la survie des…

Exercise - The new old wonderdrug